Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells.

Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, Diel I, Solomayer EF, Theocharous P, Coombes RC, Smith BM, Wunder E, Marolleau JP, Garcia J, Pantel K.

Cytotherapy. 1999;1(5):377-88. doi: 10.1080/0032472031000141283.

PMID:
20426539
2.

A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation.

Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, Pantel K, Solomayer E.

Cancer. 2006 Sep 1;107(5):885-92.

3.

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G.

J Clin Oncol. 2006 Apr 20;24(12):1940-9. Erratum in: J Clin Oncol. 2006 Jul 1;24(19):3221.

PMID:
16622270
4.

Cancer stem cells: an old idea--a paradigm shift.

Wicha MS, Liu S, Dontu G.

Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6.

5.

Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy.

Becker S, Becker-Pergola G, Wallwiener D, Solomayer EF, Fehm T.

Breast Cancer Res Treat. 2006 May;97(1):91-6. Epub 2005 Dec 1.

PMID:
16319975
6.

A pooled analysis of bone marrow micrometastasis in breast cancer.

Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K.

N Engl J Med. 2005 Aug 25;353(8):793-802.

7.

Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells.

Fehm T, Solomayer EF, Meng S, Tucker T, Lane N, Wang J, Gebauer G.

Cytotherapy. 2005;7(2):171-85. Review.

PMID:
16040397
8.

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.

Mauri D, Pavlidis N, Ioannidis JP.

J Natl Cancer Inst. 2005 Feb 2;97(3):188-94.

PMID:
15687361
9.

Sometimes a great notion--an assessment of neoadjuvant systemic therapy for breast cancer.

Davidson NE, Morrow M.

J Natl Cancer Inst. 2005 Feb 2;97(3):159-61. No abstract available.

PMID:
15687353
10.

The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence.

Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K.

Cancer. 2005 Mar 1;103(5):884-91.

11.

Circulating tumor cells in patients with breast cancer dormancy.

Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW.

Clin Cancer Res. 2004 Dec 15;10(24):8152-62.

12.

Apoptosis of circulating tumor cells in prostate cancer patients.

Larson CJ, Moreno JG, Pienta KJ, Gross S, Repollet M, O'hara SM, Russell T, Terstappen LW.

Cytometry A. 2004 Nov;62(1):46-53.

13.

Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome.

Wiedswang G, Borgen E, Kåresen R, Qvist H, Janbu J, Kvalheim G, Nesland JM, Naume B.

Clin Cancer Res. 2004 Aug 15;10(16):5342-8.

14.

Dissecting the metastatic cascade.

Pantel K, Brakenhoff RH.

Nat Rev Cancer. 2004 Jun;4(6):448-56. Review. No abstract available.

PMID:
15170447
15.

The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells.

Naume B, Wiedswang G, Borgen E, Kvalheim G, Kåresen R, Qvist H, Janbu J, Harbitz T, Nesland JM.

Clin Cancer Res. 2004 May 1;10(9):3091-7.

16.

Introducing the concept of breast cancer stem cells.

Waterworth A.

Breast Cancer Res. 2004;6(1):53-4. Epub 2003 Nov 20. No abstract available.

17.

Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.

Wiedswang G, Borgen E, Kåresen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B.

J Clin Oncol. 2003 Sep 15;21(18):3469-78.

PMID:
12972522
18.

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.

Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ.

J Clin Oncol. 2003 Jul 1;21(13):2600-8. Review. Erratum in: J Clin Oncol. 2003 Dec 1;21(23):4469.

PMID:
12829681
19.

Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer.

Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, Ferriere JP, Achard JL, Dauplat J, Penault-Llorca F.

Br J Cancer. 2002 Apr 8;86(7):1041-6.

20.

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.

Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B.

J Natl Cancer Inst Monogr. 2001;(30):96-102.

PMID:
11773300

Supplemental Content

Support Center